$AMBS - This stock has the potential to be a life
Post# of 29735
Posted On: 12/18/2012 2:20:06 PM
$AMBS - This stock has the potential to be a life changer for everyone who owns it right now, regardless of where you entered. We should have no trouble reaching .1-.3 in the next couple weeks (I'm calling for .1 at least by EOW), but that's still not going to be even close to the end of the ride. In this upcoming year we will most likely see MANF enter clinical trials, and all the research shows that it should be relatively easy to administer to human brains since GDNF paved the path. The only reason GDNF stalled out was because it has a problem where it sticks to other molecules, and MANF does not. GDNF also set a precedent for how to administer these types of drugs safely to humans, they're actually doing it right now in Phase II trials. It took Hermo Pharama and company a lot of time, effort, and money to find a safe way to administer GDNF safely- future roadblocks we don't have to worry about. Most importantly, MANF has significantly better data than GDNF. By 2014 AMBS may also see revenue start coming in from LymPro, and we are also expected to make a run for the Orphan Drug market which will expedite clinical trials and produce revenue potentially within 11-13 months from here. Dr. Rubinfield was not lying when he said MANF has the potential to be the greatest success of his lifetime. Those are some serious words from a man of his standing in the scientific community. He's 79 years old and worth a fortune, he has no incentive to fabricate the details of this discovery to make a quick buck off a penny stock... he's simply continuing his legacy.
MANF has the potential to tap multiple billion dollar markets, some of which are almost completely undeveloped. Any buyout would be huge for shareholders, we'll all see gains in the hundreds of percents for sure. It would also come relatively soon if it does, which is good hype for the next several weeks. What I'm really hoping for though is that AMBS finds an effective way to commercialize MANF without being bought out. If they can pull that off, then there's nothing stopping AMBS from becoming the next AMGEN. AMGEN started in pennyland too, and now its $80+ PPS. Great things have humble beginnings.
MANF has the potential to tap multiple billion dollar markets, some of which are almost completely undeveloped. Any buyout would be huge for shareholders, we'll all see gains in the hundreds of percents for sure. It would also come relatively soon if it does, which is good hype for the next several weeks. What I'm really hoping for though is that AMBS finds an effective way to commercialize MANF without being bought out. If they can pull that off, then there's nothing stopping AMBS from becoming the next AMGEN. AMGEN started in pennyland too, and now its $80+ PPS. Great things have humble beginnings.
(0)
(0)Scroll down for more posts ▼